[Experience in using the new drug moxifloxacin (Avelox, "Bayer", Germaniia) in urologic practice].
Fluoroquinolones (ciprofloxacine, ofloxacin, pefloxacin, lomefloxacin, etc.) have a long and successful history of application in the treatment of urinary infection. They are the first-line drugs in the above nosological entity. Fluoroquinolones of a new generation including moxifloxacin demonstrate a wider spectrum of antimicrobial activity, updated pharmacokinetic properties, low resistance that is are promising in the treatment of urinary infection. We tried moxifloxacin in the treatment of both complicated and uncomplicated infections of the urinary tracts. The response reached 95.7%, bacteriological effectiveness 85.7%. The drug is well tolerated, side effects were not observed. Thus, moxifloxacin can be used in the treatment of urinary and urogenital infections.
Derevianko
I I
II
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D024841:Fluoroquinolones; D006801:Humans; D000077266:Moxifloxacin; D011804:Quinolines / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin